Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.89 |
| ▸ | XDH | P47989 | 8/20 | 0.82 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17077332 | 1.00 | EGFR (0.89) | EGFRXDHNFE2L2MEN1NPC1 | |
| SCHEMBL29857121 | 0.95 | EGFR (0.81) | EGFRXDHNFE2L2MEN1NPC1 | |
| SCHEMBL17077418 | 0.94 | EGFR (1.00) | EGFRXDHNFE2L2 | |
| SCHEMBL17077420 | 0.94 | EGFR (1.00) | EGFRXDHNFE2L2 | |
| SCHEMBL17077348 | 0.90 | XDH (1.00) | EGFRXDHNFE2L2MEN1NPC1 | |
| SCHEMBL17077346 | 0.90 | XDH (1.00) | EGFRXDHNFE2L2MEN1NPC1 | |
| SCHEMBL17077383 | 0.89 | EGFR (0.89) | EGFRXDHNFE2L2 | |
| SCHEMBL17899489 | 0.89 | EGFR (0.91) | EGFRXDHNFE2L2MEN1NPC1 | |
| SCHEMBL17077385 | 0.89 | EGFR (0.89) | EGFRXDHNFE2L2 | |
| SCHEMBL17077354 | 0.89 | EGFR (0.86) | EGFRXDHNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409845-B2 | Alpha-(3,5-dimethoxybenzylidene)-alpha′-hydrocarbyl methylene cyclic ketone and preparation method thereof | PHARMAXYN LABORATORIES LTD. (CN) | 2016-08-09 | — | — | US | disclosed |
| EP-2927208-A1 | A-(3,5-DIMETHOXY BENZYLIDENE)-A'-HYDROCARBYL METHYLENE CYCLIC KETONE AND PREPARATION METHOD THEREOF | Pharmaxyn Laboratories Ltd. (CN) | 2015-10-07 | — | — | EP | disclosed |
| US-20150259271-A1 | alpha-(3,5-dimethoxybenzylidene)-alpha'-hydrocarbyl methylene cyclic ketone and preparation method thereof | PHARMAXYN LABORATORIES LTD. (CN) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259271-A1 | alpha-(3,5-dimethoxybenzylidene)-alpha'-hydrocarbyl methylene cyclic ketone and preparation method thereof | EGFR, KDR, BMI1 | EGFR 1/4885XDH 4195/4885NFE2L2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.